Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New condom material tested for safety and comfort

NCT ID NCT06079060

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new synthetic nitrile condom against a standard latex condom in 305 couples. Each couple used both types five times to see how often they broke or slipped. The goal was to see if the new condom works as well as latex for preventing sexually transmitted diseases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

305 people

The number who actually took part.

Started

Oct 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be between the ages of 18 and 45 years (inclusive); 2. Be literate (able to read a newspaper or letter easily); 3. Have been in an exclusive (monogamous) sexual relationship with partner for at least 3 months; and intend to continue to be an exclusive (monogamous) sexual relationship with their spouse or partner while participating in this research study; 4. Be sexually active (defined as having at least one vaginal coital act per week); 5. Willing to give informed consent; 6. Willing to complete the male condom coital use reports; 7. Willing to use the study condoms as directed; 8. Agree to use only the study lubricant provided; 9. Agree to only use the study condoms sequentially during time of participation 10. Willing to adhere to the follow-up schedule and all study procedures; 11. Willing to provide research study staff with an address, phone number or other locator information while participating in the study; 12. Willing to participate in the study for the duration of 10 condom uses (approximately 2-3 months); 13. Willing to provide photo identification and/or have fingerprint scan to exclude co-enrolment in other research projects; 14. Female partner using hormonal or other non-barrier contraception (e.g. OCs, injectable, implant, Intrauterine device (IUD), or have had a tubal sterilization) or male partner vasectomised; 15. Agree to return any unopened condoms; 16. Male partner willing to ejaculate during vaginal intercourse; 17. Male partner willing to hold on to the condom ring when withdrawing the erect penis after sexual intercourse; 18. Agree to not bring study condoms in contact with genital or oral piercing jewelry 19. EAH: Both partners have valid personal email and operable mobile phones; 20. Former participant in Karex02 Study: male partner measures at least 118 mm in girth of erect penis. 21. Agree that information provided in Karex02 study may be used and combined with the information in this study Exclusion Criteria: 1. Female partner is pregnant or desires to become pregnant during the time of the research study; 2. Either partner is known to be HIV positive (based on self report \[EAH\] or documented HIV-negative test result within past two months; 3. Self-reported history of recurrent sexually transmitted infection (e.g. gonorrhea, syphilis, Chlamydia); 4. Male partner has known erectile or ejaculatory dysfunction; 5. Either partner has genital piercing jewelry, uses genital beading or uses sex toys, drugs, medications or non-study devices that can affect sexual performance; 6. Either partner has known sensitivities or allergies to latex, synthetic nitrile, vaginal/sexual lubricants or lubricants used on condoms; 7. Either partner reports symptoms of STI (EAH) or has observable evidence of STI as determined through syndromic diagnosis and vaginal/penile examination (MRU); 8. Either partner is currently participating in another condom study; 9. Either partner is a past or current employee of Essential Access Health, University of the Witwatersrand, or Karex; 10. Either partner is a sex worker.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sexually transmitted diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Essential Access Health

    Berkeley, California, 94710, United States

  • Essential Access Health

    Los Angeles, California, 90010, United States

  • MRU (MatCH Research Unit)

    Durban, 4000, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.